Hedge Fund - Broadwood Capital
News, Interviews, and Investor Letters
- 1 - 10
- Next >>
The recent stock market pullback has definitely pushed companies’ valuations into cheap territory, so hedge funds and other money managers have been busy amassing “cheap” equities.
Neal C. Bradsher's Broadwood Capital revealed in a recent Form 4 filing with the SEC that it has purchased an additional 2.43 million shares of BioTime, Inc.
Redmile Group Fortifies Position In Array Biopharma Inc (ARRY); Broadwood Capital Boosts Stake In STAAR Surgical Company (STAA)
Jeremy Green, the manager of Redmile Group, is still bullish on Array Biopharma Inc (NASDAQ:ARRY) having further increased his holding of the stock.
As a new filing with the Securities and Exchange revealed, Neal C. Bradsher's Broadwood Capital has acquired a significant position in BioTime, Inc.
Neal C. Bradsher, the manager of Broadwood Capital, is still bullish on BioTime, Inc. (NYSEMKT:BTX) and has further increased his fund's stake in the company.
In its filing with the Securities and Exchange Commission, Neal C. Bradsher's Broadwood Capital has disclosed further reducing its stake in Questcor Pharmaceuticals Inc (NASDAQ:QCOR).
Neal C. Bradsher’s Broadwood Capital dumped some shares of its holding in Questcor Pharmaceuticals Inc (NASDAQ:QCOR), a newly amended filing with the SEC showed.
Neal C. Bradsher's Broadwood Capital has trimmed its stake in Questcor Pharmaceuticals Inc (NASDAQ:QCOR) by selling 20,000 shares.